The U.S. Food and Drug Administration said Tuesday that quick antigen tests people take at home may be less sensitive to picking up the Omicron variant of the coronavirus, but
The agency says early data suggests the home tests, known as "antigen" tests, may produce more false negatives than they do with earlier forms of COVID-19.
Preliminary research by the FDA, in collaboration with the NIH's RADx program, used samples from patients confirmed to be infected with the omicron strain of the virus to study the performance of antigen tests.
Rapid Covid home tests are more likely to give a false negative with the heavily-mutated Omicron variant compared to earlier strains, the US Food and Drug Administration (FDA) said Tuesday.
Rapid Covid home tests are more likely to give a false negative with the heavily-mutated Omicron variant compared to earlier strains, the US Food and Drug Administration (FDA) said Tuesday.
WEDNESDAY, Dec. 29, 2021 (HealthDay News) -- Early research suggests that some rapid COVID-19 tests may be less able to detect the Omicron variant, the U.S. Food and Drug Administration
The Food and Drug Administration (FDA) on Tuesday warned that antigen tests may be less effective in detecting the highly contagious omicron variant of COVID-19.
As many Americans turn to at-home COVID-19 testing rather than waiting in line, the latest update from the FDA and doctors suggest there’s more to be learned about rapid tests when it comes to the omicron variant. In a statement released Tuesday, the U.S.
"The bottom line is the tests still detect COVID-19 whether it is delta or alpha or omicron," says Dr. Emily Volk, president of the College of American Pathologists.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
FDA warns at-home COVID-19 tests may not always be able to detect the omicron variant | Since Then
